B. Riley lowered the firm’s price target on Novavax (NVAX) to $16 from $18 and keeps a Buy rating on the shares. Novavax’s Q3 top and bottom line results were ahead of the Street’s expectations, driven by increasingly diversified revenue streams, the analyst tells investors in a research note. The earlier-stage pipeline represents a second engine of value creation, notably four active programs — C. difficile, shingles, RSV combination, and pandemic flu, the firm adds.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Novavax’s Strong Financial Outlook and Strategic Partnerships Support Buy Rating
- Novavax Reports Q3 2025 Earnings and Strategic Progress
- Novavax’s Q3 2025 Earnings Call: Optimistic Outlook
- Novavax reports Q3 EPS ($1.25), consensus (92c)
- Novavax raises FY25 adjusted revenue view to $1.04B-$1.06B from $1B-$1.05B